In childhood HUS, heme from haemolysis activated the kallikrein–kinin system

Design

Translational study: patient samples, mouse models and in vitro experiments

Population

34 children with E. coli-associated HUS, plus mouse models

Primary outcome

Kallikrein–kinin system activation

Effect

Kininogen degradation in 10/34 and reduced pre-kallikrein in 17/32; blocked by C1-inhibitor in experiments

This translational study, published in August, examined 34 children with E. coli-associated haemolytic uraemic syndrome, infected mice and laboratory models. Degraded high-molecular-weight kininogen, a sign of kallikrein–kinin activation, was found in 10 of 34 children and tracked haemolysis severity; reduced pre-kallikrein in 17 of 32 tracked kidney dysfunction.

In experiments, heme bound to and activated factor XII, driving kallikrein activity and bradykinin release. This was blocked by hemopexin and C1-inhibitor, and absent in factor XII-deficient plasma. In mice, C1-inhibitor pre-treatment prevented kininogen degradation after induced haemolysis.

This suggests a mechanism by which haemolysis itself may drive inflammation and vascular injury in HUS, and identifies a druggable target. It is mechanistic, with no clinical intervention tested in patients.

• Kallikrein–kinin activation was seen in a subset of children with E. coli HUS.
• Its markers tracked haemolysis and kidney dysfunction.
• C1-inhibitor blocked the pathway in laboratory and mouse experiments only.
• Supportive care remains the treatment for E. coli HUS.

Why it matters

It points to a new therapeutic target in a disease managed only supportively.

Don't overread it

This is mechanistic and animal work; no therapy was tested in children.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.